140 related articles for article (PubMed ID: 37470325)
1. Homoharringtonine-Based Induction Therapy Reduces the Recurrence Rate of Pediatric Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation.
Wang B; Wen X; Zhang R; Zhu G; Wu Y; Zhang Y; Lin W; Yu J; Fan J; Li J; Yang J; Qin M; Zheng H
Cell Transplant; 2023; 32():9636897231183559. PubMed ID: 37470325
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
[TBL] [Abstract][Full Text] [Related]
3. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of 7 cases of pediatric acute myeloid leukemia with DEK-NUP214 fusion gene].
Li XL; Liu LP; Wan Y; Liu F; Chen X; Ren YY; Ruan M; Guo Y; Zhu XF; Yang WY
Zhonghua Er Ke Za Zhi; 2023 Apr; 61(4):357-362. PubMed ID: 37011983
[No Abstract] [Full Text] [Related]
5. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era.
Xue YJ; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1611-1620. PubMed ID: 30537550
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
8. Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia.
Meshinchi S; Leisenring WM; Carpenter PA; Woolfrey AE; Sievers EL; Radich JP; Sanders JE
Biol Blood Marrow Transplant; 2003 Nov; 9(11):706-13. PubMed ID: 14652854
[TBL] [Abstract][Full Text] [Related]
9. Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2020 Dec; 99(12):2911-2925. PubMed ID: 33000361
[TBL] [Abstract][Full Text] [Related]
10. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation: a retrospective study from a single institution.
Lin CH; Chen TC; Shih YH; Chou CW; Hsu CY; Li PH; Teng CJ
J Int Med Res; 2022 Feb; 50(2):3000605221078466. PubMed ID: 35187981
[TBL] [Abstract][Full Text] [Related]
13. [Allogeneic hematopoietic stem cell transplantation in acute leukemia patients with the SET-NUP214 fusion gene: Efficacy and survival analysis].
Xia J; Zhao Y; Chen F; Miao M; Qiu HY; Ma X; Tang XW; Wang Y; Wu XJ; Fu ZZ; Wu DP; Chen SN
Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):410-415. PubMed ID: 37032136
[No Abstract] [Full Text] [Related]
14. Pediatric acute myeloid leukemia patients with
Yang W; Qin M; Jia C; Yang J; Chen W; Luo Y; Jing Y; Wang B
Hematology; 2022 Dec; 27(1):583-589. PubMed ID: 35617149
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial.
Hyakuna N; Hashii Y; Ishida H; Umeda K; Takahashi Y; Nagasawa M; Yabe H; Nakazawa Y; Koh K; Goto H; Fujisaki H; Matsumoto K; Kakuda H; Yano M; Tawa A; Tomizawa D; Taga T; Adachi S; Kato K
Pediatr Blood Cancer; 2019 Oct; 66(10):e27875. PubMed ID: 31309713
[TBL] [Abstract][Full Text] [Related]
16. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
[No Abstract] [Full Text] [Related]
17. [Efficacy and Relapse Prediction Model of Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Acute Leukemia].
Wang XN; Zhang Y; Liu XW; Ren J; Zhao J; He PC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):696-702. PubMed ID: 34105459
[TBL] [Abstract][Full Text] [Related]
18. Extramedullary relapse of acute leukemia after allogeneic hematopoietic stem cell transplantation: different characteristics between acute myelogenous leukemia and acute lymphoblastic leukemia.
Ge L; Ye F; Mao X; Chen J; Sun A; Zhu X; Qiu H; Jin Z; Miao M; Fu C; Ma X; Chen F; Xue S; Ruan C; Wu D; Tang X
Biol Blood Marrow Transplant; 2014 Jul; 20(7):1040-7. PubMed ID: 24704575
[TBL] [Abstract][Full Text] [Related]
19. Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Tong X; Li M; Jin J; Li Y; Li L; Peng Y; Huang L; Xu B; Meng F; Mao X; Huang L; Huang W; Zhang D
Int J Cancer; 2023 May; 152(10):2123-2133. PubMed ID: 36594582
[TBL] [Abstract][Full Text] [Related]
20. [Clinical Analysis for Patients with AML Treated after Allo-HSCT].
Wang QY; Dong YJ; Liang ZY; Yin Y; Liu W; Xu WL; Sun YH; Han N; Li Y; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1105-1114. PubMed ID: 32798384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
